

Referenzen Gynäkologenratgeber 08/2021

1. Begemann H. Das Blut als Organ. In: Begemann H, Bolck F, Lang FJ, et al., eds. *Die Organe: Die Organstruktur als Grundlage der Organleistung und Organerkrankung I*. Berlin, Heidelberg: Springer Berlin Heidelberg; 1960:1-43.
2. Bundesärztekammer. Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen. *Deutsches Ärzteblatt*. 2014.
3. Wang Y, Zhao S. Placental Blood Circulation. <https://www.ncbi.nlm.nih.gov/books/NBK53254/>. Updated January 1, 2010. Accessed April 30, 2019.
4. Christou I, Mallis P, Michalopoulos E, et al. Evaluation of Peripheral Blood and Cord Blood Platelet Lysates in Isolation and Expansion of Multipotent Mesenchymal Stromal Cells. *Bioengineering (Basel)*. 2018;5(1). doi:10.3390/bioengineering5010019.
5. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 13 Herstellungserlaubnis. https://www.gesetze-im-internet.de/amg_1976/__13.html. Updated July 22, 2019. Accessed July 22, 2019.
6. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 21 Zulassungspflicht. https://www.gesetze-im-internet.de/amg_1976/__21.html. Updated July 22, 2019. Accessed July 22, 2019.
7. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 21a Genehmigung von Gewebezubereitungen. https://www.gesetze-im-internet.de/amg_1976/__21a.html. Updated July 22, 2019. Accessed July 22, 2019.
8. Bundesamt für Justiz. Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz - AMG) § 22 Zulassungsunterlagen. https://www.gesetze-im-internet.de/amg_1976/__22.html. Updated July 22, 2019. Accessed July 22, 2019.
9. Bundesamt für Justiz. Verordnung über die Anwendung der Guten Herstellungspraxis bei der Herstellung von Arzneimitteln und Wirkstoffen und über die Anwendung der Guten fachlichen Praxis bei der Herstellung von Produkten menschlicher Herkunft (Arzneimittel- und Wirkstoffherstellungsverordnung - AMWHV) § 4 Personal. https://www.gesetze-im-internet.de/amwhv/__4.html. Updated July 22, 2019. Accessed July 22, 2019.
10. Galieva LR, Mukhamedshina YO, Arkhipova SS, Rizvanov AA. Human Umbilical Cord Blood Cell Transplantation in Neuroregenerative Strategies. *Front Pharmacol*. 2017;8:628. doi:10.3389/fphar.2017.00628.
11. Sieburg HB, Cattarossi G, Muller-Sieburg CE. Lifespan differences in hematopoietic stem cells are due to imperfect repair and unstable mean-reversion. *PLoS Comput Biol*. 2013;9(4):e1003006. doi:10.1371/journal.pcbi.1003006.
12. Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. *Blood*. 2010;116(4):625-627. doi:10.1182/blood-2010-01-259028.
13. Park YM, Bochner BS. Eosinophil survival and apoptosis in health and disease. *Allergy Asthma Immunol Res*. 2010;2(2):87-101. doi:10.4168/aaair.2010.2.2.87.
14. Siracusa MC, Comeau MR, Artis D. New insights into basophil biology: initiators, regulators, and effectors of type 2 inflammation. *Ann N Y Acad Sci*. 2011;1217:166-177. doi:10.1111/j.1749-6632.2010.05918.x.
15. Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. *J Exp Med*. 2017;214(7):1913-1923. doi:10.1084/jem.20170355.
16. Kaestner L, Bogdanova A. Regulation of red cell life-span, erythropoiesis, senescence, and clearance. *Front Physiol*. 2014;5:269. doi:10.3389/fphys.2014.00269.

17. Franco RS. Measurement of red cell lifespan and aging. *Transfus Med Hemother*. 2012;39(5):302-307. doi:10.1159/000342232.
18. Seifert M, Küppers R. Human memory B cells. *Leukemia*. 2016;30(12):2283-2292. doi:10.1038/leu.2016.226.
19. Broxmeyer HE. *StemBook: Cord blood hematopoietic stem cell transplantation* *. Cambridge (MA); 2008. <https://www.ncbi.nlm.nih.gov/books/NBK44751/>. Accessed April 29, 2019.
20. Jin HJ, Bae YK, Kim M, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. *Int J Mol Sci*. 2013;14(9):17986-18001. doi:10.3390/ijms140917986.
21. Davies JE, Walker JT, Keating A. Concise Review: Wharton's Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells. *Stem Cells Transl Med*. 2017;6(7):1620-1630. doi:10.1002/sctm.16-0492.
22. Marino L, Castaldi MA, Rosamilio R, et al. Mesenchymal Stem Cells from the Wharton's Jelly of the Human Umbilical Cord: Biological Properties and Therapeutic Potential. *Int J Stem Cells*. 2019. doi:10.15283/ijsc18034.
23. Dalous J, Larghero J, Baud O. Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives. *Pediatr Res*. 2012;71(4 Pt 2):482-490. doi:10.1038/pr.2011.67.
24. Willing AE, Eve DJ, Sanberg PR. Umbilical cord blood transfusions for prevention of progressive brain injury and induction of neural recovery: an immunological perspective. *Regen Med*. 2007;2(4):457-464. doi:10.2217/17460751.2.4.457.
25. Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood. *Expert Opin Biol Ther*. 2018;18(2):121-134. doi:10.1080/14712598.2018.1402002.
26. Bönig H, Heiden M, Schüttrumpf J, Müller MM, Seifried E. Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2011;54(7):791-796. doi:10.1007/s00103-011-1305-2.
27. Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. *Bone Marrow Transplant*. 2019. doi:10.1038/s41409-019-0546-9.
28. Gluckman Eliane, Broxmeyer Hal E., Auerbach Arleen D., et al. Hematopoietic Reconstitution in a Patient with Fanconi's Anemia by Means of Umbilical-Cord Blood from an HLA-Identical Sibling // Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. *N Engl J Med*. 1989;321(17):1174-1178. doi:10.1056/NEJM198910263211707.
29. Dessels C, Alessandrini M, Pepper MS. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. *Stem Cells Transl Med*. 2018;7(9):643-650. doi:10.1002/sctm.17-0244.
30. Ballen K. Update on umbilical cord blood transplantation. *F1000Res*. 2017;6:1556. doi:10.12688/f1000research.11952.1.
31. ClinicalTrials.gov. NCT03913312: Multicenter, One-arm, Phase II Clinical Study of Decitabine Combined With Unrelated Cord Blood Transplantation for the Treatment of Acute Myeloid Leukemia (AML) in the Elderly. <https://clinicaltrials.gov/ct2/show/NCT03913312>. Accessed July 21, 2021.
32. ClinicalTrials.gov. NCT03441958: A Phase I-II Open-label Study of Non-myeloablative-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With

- High-risk Multiple Myeloma. <https://clinicaltrials.gov/ct2/show/NCT03441958>. Accessed July 21, 2021.
33. ClinicalTrials.gov. NCT01451502: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units. <https://clinicaltrials.gov/ct2/show/NCT01451502>. Accessed July 21, 2021.
 34. ClinicalTrials.gov. NCT02745717: The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia. <https://clinicaltrials.gov/ct2/show/NCT02745717>. Accessed July 21, 2021.
 35. ClinicalTrials.gov. NCT03881774: Clinical Study of Cord Blood Derived CAR-T Cells in Patients With Refractory/Relapsed B Cell Leukemia/Lymphoma Who Are Failed for Autologous CAR-T Cells or Autologous CAR-T Can Not be Prepared. <https://clinicaltrials.gov/ct2/show/NCT03881774?term=%22cord+blood%22%2C+%22CAR+T%22&rank=1>. Accessed July 21, 2021.
 36. ClinicalTrials.gov. NCT01861093: A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients. <https://clinicaltrials.gov/ct2/show/NCT01861093>. Accessed July 21, 2021.
 37. ClinicalTrials.gov. NCT01247701: Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies (UCAML). <https://clinicaltrials.gov/ct2/show/NCT01247701>. Accessed July 21, 2021.
 38. ClinicalTrials.gov. NCT00739141: A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. <https://clinicaltrials.gov/ct2/show/NCT00739141>. Accessed July 21, 2021.
 39. ClinicalTrials.gov. NCT01553461: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications. <https://clinicaltrials.gov/ct2/show/NCT01553461>. Accessed July 21, 2021.
 40. ClinicalTrials.gov. NCT02730299: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord[®], Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies. <https://clinicaltrials.gov/ct2/show/NCT02730299>. Accessed December 7, 2020.
 41. ClinicalTrials.gov. NCT01962636: Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases. <https://clinicaltrials.gov/ct2/show/NCT01962636>. Accessed July 21, 2021.
 42. ClinicalTrials.gov. NCT03096782: Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment. <https://clinicaltrials.gov/ct2/show/NCT03096782>. Accessed July 21, 2021.
 43. ClinicalTrials.gov. NCT01619761: Natural Killer Cells in Allogeneic Cord Blood Transplantation. <https://clinicaltrials.gov/ct2/show/NCT01619761>. Accessed December 7, 2020.
 44. ClinicalTrials.gov. NCT02727803: Personalized NK Cell Therapy in Cord Blood Transplantation. <https://clinicaltrials.gov/ct2/show/NCT02727803>. Accessed July 21, 2021.
 45. ClinicalTrials.gov. NCT01729091: Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma. <https://clinicaltrials.gov/ct2/show/NCT01729091>. Accessed July 21, 2021.
 46. ClinicalTrials.gov. NCT03056339: Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With

Relapsed/Refractory B-Lymphoid Malignancies.

<https://clinicaltrials.gov/ct2/show/NCT03056339?term=%22cord+blood%22%2C+CAR%2C+NK&rank=1>. Accessed July 21, 2021.

47. ClinicalTrials.gov. NCT03420963: Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults. <https://clinicaltrials.gov/ct2/show/NCT03420963>. Accessed July 21, 2021.
48. ClinicalTrials.gov. NCT03735277: Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke. <https://clinicaltrials.gov/ct2/show/NCT03735277>. Accessed July 21, 2021.
49. ClinicalTrials.gov. NCT02433509: Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke. <https://clinicaltrials.gov/ct2/show/NCT02433509>. Accessed July 21, 2021.
50. ClinicalTrials.gov. NCT02551003: A Multi-Centre Safety and Efficacy Study of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonates Encephalopathy in China. <https://clinicaltrials.gov/ct2/show/NCT02551003>. Accessed July 21, 2021.
51. ClinicalTrials.gov. NCT03696745: The Treatment of Premature Infants With Brain Injury by Autologous Umbilical Cord Blood Stem Cells. <https://clinicaltrials.gov/ct2/show/NCT03696745>. Accessed July 21, 2021.
52. ClinicalTrials.gov. NCT03473301: A Phase I/II Study of Allogeneic Umbilical Cord Blood and Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Infusions in Children With Cerebral Palsy. <https://clinicaltrials.gov/ct2/show/NCT03473301?term=kurtzberg&rank=3>. Accessed July 21, 2021.
53. ClinicalTrials.gov. NCT03826498: Allogeneic Cord Blood Transfusion in Patients With Cerebral Palsy. <https://clinicaltrials.gov/ct2/show/NCT03826498>. Accessed July 21, 2021.
54. ClinicalTrials.gov. NCT03558269: Pilot Study to Assess the Efficacy of Autologous Umbilical Cord Blood Treatment of Brain and Heart Injury in Neonates With Congenital Heart Defect. <https://clinicaltrials.gov/ct2/show/NCT03558269>. Accessed July 21, 2021.
55. ClinicalTrials.gov. NCT03431480: Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation. <https://clinicaltrials.gov/ct2/show/NCT03431480>. Accessed July 21, 2021.
56. ClinicalTrials.gov. NCT01883076: Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome. <https://clinicaltrials.gov/ct2/show/NCT01883076>. Accessed July 21, 2021.
57. ClinicalTrials.gov. NCT03779711: Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2). <https://clinicaltrials.gov/ct2/show/NCT03779711>. Accessed June 21, 2019.
58. ClinicalTrials.gov. NCT01632475: Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia. <https://clinicaltrials.gov/ct2/show/NCT01632475>. Accessed July 21, 2021.
59. ClinicalTrials.gov. NCT03378063: Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study. <https://clinicaltrials.gov/ct2/show/NCT03378063?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=124>. Accessed July 21, 2021.
60. ClinicalTrials.gov. NCT02932826: Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells on Autoimmune Diabetes. <https://clinicaltrials.gov/ct2/show/NCT02932826>. Accessed July 21, 2021.

61. ClinicalTrials.gov. NCT03835312: Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus. <https://clinicaltrials.gov/ct2/show/NCT03835312>. Accessed July 21, 2021.
62. ClinicalTrials.gov. NCT03011021: Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells With Liraglutide on Autoimmune Diabetes. <https://clinicaltrials.gov/ct2/show/NCT03011021>. Accessed July 21, 2021.
63. ClinicalTrials.gov. NCT03016806: Umbilical Cord Blood Transplantation From Unrelated Donors. <https://clinicaltrials.gov/ct2/show/NCT03016806>. Accessed July 21, 2021.
64. ClinicalTrials.gov. NCT02926300: Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease. <https://clinicaltrials.gov/ct2/show/NCT02926300?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=142>. Accessed July 21, 2021.
65. ClinicalTrials.gov. NCT02918123: Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis. <https://clinicaltrials.gov/ct2/show/NCT02918123?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=143>. Accessed July 21, 2021.
66. ClinicalTrials.gov. NCT03618784: A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis. <https://clinicaltrials.gov/ct2/show/NCT03618784?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&draw=2&rank=131>. Accessed July 21, 2021.
67. ClinicalTrials.gov. NCT02254863: Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells. <https://clinicaltrials.gov/ct2/show/NCT02254863>. Accessed July 21, 2021.
68. ClinicalTrials.gov. NCT03084861: A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy. [Terminated]. <https://clinicaltrials.gov/ct2/show/NCT03084861>. Accessed July 21, 2021.
69. ClinicalTrials.gov. NCT02434965: Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy. <https://clinicaltrials.gov/ct2/show/NCT02434965?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&rank=11>. Accessed August 9, 2019.
70. Weyand M, Kececioglu D, Schulze-Everding A, et al. Die chirurgischen Behandlungsmöglichkeiten des Hypoplastischen Linksherzsyndroms. *Dtsch Arztebl International*. 1998;95(37):A-2256. <https://www.aerzteblatt.de/int/article.asp?id=13039>.
71. ClinicalTrials.gov. NCT03779711: Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (AutoCell-S2). <https://clinicaltrials.gov/ct2/show/NCT03779711?term=NOT+peripheral&recrs=abdf&intr=%22cord+blood%22&rank=37>. Accessed July 21, 2021.
72. ClinicalTrials.gov. NCT03172117: Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial. <https://clinicaltrials.gov/ct2/show/NCT03172117?term=cord+blood%3B+alzheimer&recrs=abdf&draw=2&rank=1>. Updated August 17, 2018. Accessed August 6, 2020.

73. Hansen M, Zatula N, Riammer S, Lehmann M. Safe enzymatic isolation and expansion of mesenchymal stromal cells from cryopreserved umbilical cord tissue. *JCB*. 2019;4(1-2):51-56. doi:10.3233/JCB-180011.
74. Beeravolu N, McKee C, Alamri A, et al. Isolation and Characterization of Mesenchymal Stromal Cells from Human Umbilical Cord and Fetal Placenta. *J Vis Exp*. 2017;(122). doi:10.3791/55224.
75. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical Cord as Prospective Source for Mesenchymal Stem Cell-Based Therapy. *Stem Cells Int*. 2016;2016:6901286. doi:10.1155/2016/6901286.
76. Park YB, Ha CW, Kim JA, et al. Single-stage cell-based cartilage repair in a rabbit model: cell tracking and in vivo chondrogenesis of human umbilical cord blood-derived mesenchymal stem cells and hyaluronic acid hydrogel composite. *Osteoarthr Cartil*. 2017;25(4):570-580. doi:10.1016/j.joca.2016.10.012.
77. Kargozar S, Mozafari M, Hashemian SJ, et al. Osteogenic potential of stem cells-seeded bioactive nanocomposite scaffolds: A comparative study between human mesenchymal stem cells derived from bone, umbilical cord Wharton's jelly, and adipose tissue. *J Biomed Mater Res Part B Appl Biomater*. 2018;106(1):61-72. doi:10.1002/jbm.b.33814.
78. Yang C, Wang G, Ma F, et al. Repeated injections of human umbilical cord blood-derived mesenchymal stem cells significantly promotes functional recovery in rabbits with spinal cord injury of two noncontinuous segments. *Stem Cell Res Ther*. 2018;9(1):136. doi:10.1186/s13287-018-0879-0.
79. Ertl J, Pichlsberger M, Tuca A-C, et al. Comparative study of regenerative effects of mesenchymal stem cells derived from placental amnion, chorion and umbilical cord on dermal wounds. *Placenta*. 2018;65:37-46. doi:10.1016/j.placenta.2018.04.004.
80. Moroncini G, Paolini C, Orlando F, et al. Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. *PLoS ONE*. 2018;13(6):e0196048. doi:10.1371/journal.pone.0196048.
81. ClinicalTrials.gov. Search Results 06/14/2019: Keywords: "umbilical cord" AND "mesenchymal stem cells"; Filters: Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies. 2019.
https://clinicaltrials.gov/ct2/results?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&flds=abdefgikpy&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&Search=Apply. Accessed June 14, 2019.
82. ClinicalTrials.gov. Search Results 06/14/2019: Keywords: "umbilical cord" AND "mesenchymal stem cells"; Filters: Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies; Phase 2. 2019.
https://clinicaltrials.gov/ct2/results?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&recrs=b&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=&rslt=&phase=1&Search=Apply. Accessed June 14, 2019.
83. ClinicalTrials.gov. NCT03521323: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury : A Multicenter, Randomized, Controlled Trial. <https://clinicaltrials.gov/ct2/show/NCT03521323>. Accessed July 21, 2021.
84. ClinicalTrials.gov. NCT03505034: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Late Stage of Chronic Spinal Cord Injury : A Multicenter, Prospective, Cohort Study. <https://clinicaltrials.gov/ct2/show/NCT03505034>. Accessed July 21, 2021.

85. ClinicalTrials.gov. NCT03521336: The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Sub-Acute Spinal Cord Injury : A Multicenter, Randomized, Controlled Trial. <https://clinicaltrials.gov/ct2/show/NCT03521336>. Accessed March 15, 2021.
86. ClinicalTrials.gov. NCT04314687: Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in Children. <https://clinicaltrials.gov/ct2/show/NCT04314687>. Accessed July 21, 2021.
87. ClinicalTrials.gov. NCT03383081: A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-OA) Therapy for Patients With Osteoarthritis. <https://clinicaltrials.gov/ct2/show/NCT03383081>. Accessed July 21, 2021.
88. ClinicalTrials.gov. NCT03818737: Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA). <https://clinicaltrials.gov/ct2/show/NCT03818737>. Accessed July 21, 2021.
89. ClinicalTrials.gov. NCT02968459: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars. <https://clinicaltrials.gov/ct2/show/NCT02968459>. Updated February 21, 2020. Accessed July 21, 2021.
90. ClinicalTrials.gov. NCT03386708: A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cell (19#iSCLife®-CSD) Therapy for Patients With Healing Poor After Uterus Injury. <https://clinicaltrials.gov/ct2/show/NCT03386708>. Accessed July 21, 2021.
91. ClinicalTrials.gov. NCT03592849: The Efficacy and Safety of Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchymal Stem Cells in Infertile Women With Thin Endometrium or Endometrial Scarring. <https://clinicaltrials.gov/ct2/show/NCT03592849>. Accessed July 21, 2021.
92. ClinicalTrials.gov. NCT04011059: Randomized Study as Proof of Concept of Coronary Revascularization Surgery With Injection of Wharton's Jelly-derived Mesenchymal Cells and Placement of an Epicardial Extracellular Matrix Patch Seeded With WJ-MSCs in Patients With Ischemic Cardiomyopathy. <https://clinicaltrials.gov/ct2/show/NCT04011059>. Accessed July 21, 2021.
93. ClinicalTrials.gov. NCT03765957: Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells. <https://clinicaltrials.gov/ct2/show/NCT03765957>. Accessed July 21, 2021.
94. ClinicalTrials.gov. NCT03562065: Treatment of Refractory Systemic Lupus Erythematosus by Injection of Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord. <https://clinicaltrials.gov/ct2/show/NCT03562065>. Accessed July 21, 2021.
95. Bing Liang, Junhui Chen, Tao Li, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. <http://chinaxiv.org/abs/202002.00084>. Updated February 27, 2020.
96. Atluri S, Manchikanti L, Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. *Pain Physician*. 2020;23(2):E71-E83.
97. Assistance Publique - Hôpitaux de Paris. NCT04333368: Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS.

<https://clinicaltrials.gov/ct2/show/NCT04333368>. Updated April 22, 2020. Accessed April 22, 2020.

98. ClinicalTrials.gov. Liste laufender Studien zur Anwendung von MSCs aus Nabelschnurgewebe zur Behandlung von COVID-19-Lungenentzündung, Teil-1.
<https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=&intr=UC-MSc&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f>. Accessed July 21, 2021.
99. ClinicalTrials.gov. Liste laufender Studien zur Anwendung von MSCs aus Nabelschnurgewebe zur Behandlung von COVID-19-Lungenentzündung, Teil-2.
<https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=&intr=WJ-MSc&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=f>. Accessed July 21, 2021.
100. ClinicalTrials.gov. NCT02968459: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars.
<https://clinicaltrials.gov/ct2/show/NCT02968459?term=%22umbilical+cord%22%2C+%22mesenchymal+stem+cells%22&recrs=abdf>. Accessed December 7, 2020.
101. ClinicalTrials.gov. NCT03724617: Clinical Study of Stem Cells in the Treatment of Thin Endometrium. <https://clinicaltrials.gov/ct2/show/NCT03724617>. Accessed June 13, 2019.
102. ClinicalTrials.gov. NCT03818737: Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA).
<https://clinicaltrials.gov/ct2/show/NCT03818737>. Accessed March 15, 2021.
103. Kim Y-J, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. *Crit Rev Oncol Hematol*. 2011;79(2):112-126. doi:10.1016/j.critrevonc.2010.07.009.
104. Sarvaria A, Basar R, Mehta RS, et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. *Blood*. 2016;128(10):1346-1361. doi:10.1182/blood-2016-01-695122.
105. Novartis Pharma. Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) | Novartis. <https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel>. Accessed February 28, 2019.
106. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. *N Engl J Med*. 2018;379(1):64-73. doi:10.1056/NEJMra1706169.
107. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med*. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866.
108. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447.
109. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980.

110. ClinicalTrials.gov. NCT03579927: Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma. <https://clinicaltrials.gov/ct2/show/NCT03579927?term=%22cord+blood%22%2C+CAR%2C+NK&rank=2>. Accessed June 18, 2019.
111. National Cancer Institute. CAR T Cells: Engineering Immune Cells to Treat Cancer. <https://www.cancer.gov/about-cancer/treatment/research/car-t-cells>. Updated December 14, 2017. Accessed March 19, 2019.
112. Novartis Pharma. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice | Novartis. <https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019>. Accessed February 28, 2019.
113. U.S. Food & Drug Administration, Office of the Commissioner. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma: Yescarta is the second gene therapy product approved in the U.S. <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm581216.htm>. Updated March 21, 2018. Accessed March 22, 2019.
114. Novartis Pharma. Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma | Novartis. <https://www.novartis.com/news/media-releases/kymriahtisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma>. Accessed February 18, 2019.
115. European Medicines Agency. Yescarta: axicabtagene ciloleucel. <https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta>. Updated January 23, 2019. Accessed March 22, 2019.
116. Das RK, Vernau L, Grupp SA, Barrett DM. Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. *Cancer Discov*. 2019. doi:10.1158/2159-8290.CD-18-1314.
117. Clague RB, Herold M, Bayer M, Tauchmannová H, Ferencik M, Killinger Z. *Dictionary of Rheumatic Disease: Naive lymphocytes*. 1. Aufl. s.l.: Springer Verlag Wien; 2009. <http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=305925>.
118. Frumento G, Zheng Y, Aubert G, et al. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. *Am J Transplant*. 2013;13(1):45-55. doi:10.1111/j.1600-6143.2012.04286.x.
119. ClinicalTrials.gov. NCT03579927: Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma. <https://clinicaltrials.gov/ct2/show/NCT03579927>. Accessed December 7, 2020.